Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Hematologic Neoplasms 5Lymphoma, Non-Hodgkin 4Lymphoma 4Leukemia 4Hodgkin Disease 4Breast Neoplasms 4Leukemia, Myeloid, Acute 3Recurrence 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Multiple Myeloma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia, B-Cell 2Waldenstrom Macroglobulinemia 1Stomach Neoplasms 1Sarcoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Follicular 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphoid 1Leukemia, Biphenotypic, Acute 1Inflammatory Breast Neoplasms 1Hematologic Diseases 1Graft vs Host Disease 1Colorectal Neoplasms 1Burkitt Lymphoma 1

Interventions

ibrutinib 2fludarabine 2Sirolimus 2Rituximab 2Mycophenolic Acid 2Cyclophosphamide 2oblimersen 1Whole-Body Irradiation 1Surveys and Questionnaires 1Mesna 1KW-2478 1Hsp90 inhibitor KU757 1Filgrastim 1Busulfan 1Bortezomib 1Acupuncture Therapy 14-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Bronchiolitis Obliterans Syndrome × Mesna × Clear all
NCT04959175 2026-04-28

Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
320 enrolled
Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡